newsfilter
← Latest News
GlobeNewswire·

Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical trials of budoprutug